Gilead Sciences, INC Form 4 insider transactions

Johanna Mercier, Chief Commercial Officer of Gilead Sciences, reports the vesting and disposal of restricted stock units.

Andrew Dickinson, CFO of Gilead Sciences, reports the vesting and subsequent sale of restricted stock units.

Johanna Mercier, Chief Commercial Officer of Gilead Sciences, sold 9,513 shares of common stock at $78.03 per share on August 28, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Chief Commercial Officer of Gilead Sciences, Johanna Mercier, sold 5,490 shares of common stock at $73.98 per share on August 13, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Sandra Patterson, SVP, Controllership at Gilead Sciences, reports the vesting and subsequent disposal of restricted stock units.

Deborah H. Telman, EVP, Corporate Affairs & GC of Gilead Sciences, reports the disposition and acquisition of common stock and restricted stock units on July 25, 2024.

Merdad Parsey, Chief Medical Officer of Gilead Sciences, reports the sale of 2,000 shares of common stock on July 1, 2024, under a pre-arranged Rule 10b5-1 trading plan.

Gilead Sciences increases its holdings in Assembly Biosciences via a private placement, acquiring common stock and warrants.

Andrew Dickinson, CFO of Gilead Sciences, reports the vesting and subsequent disposal of restricted stock units.

Sandra Patterson, SVP, Controllership at Gilead Sciences, reports the acquisition and disposal of common stock and restricted stock units on June 10, 2024.

Gilead Sciences CEO Daniel O'Day reports the vesting of restricted stock units and subsequent sale of shares to cover tax obligations.

Johanna Mercier, Chief Commercial Officer of Gilead Sciences, reports the vesting and subsequent sale of restricted stock units.

Merdad Parsey, Chief Medical Officer of Gilead Sciences, reports the acquisition and disposal of common stock and restricted stock units on June 10, 2024.

EVP Deborah H. Telman of Gilead Sciences reports the vesting and subsequent disposal of restricted stock units.

Director Jacqueline K. Barton reports acquisition of stock options and restricted stock units in Gilead Sciences, Inc.

Director Ted W. Love reports acquisition of Gilead Sciences stock and stock options, with immediate vesting, on May 8, 2024.

Director Javier Rodriguez reports acquisition of stock options and restricted stock units (RSUs) in Gilead Sciences, Inc.

Director Anthony Welters reports the acquisition of restricted stock units and stock options in Gilead Sciences, Inc.

Director Harish Manwani reports acquisition of restricted stock units and stock options in Gilead Sciences, along with disposition of shares to cover tax obligations.

Director Jeffrey Bluestone reports acquisition of stock options and restricted stock units in Gilead Sciences, Inc.

Director Sandra Horning reports the acquisition of stock options and restricted stock units in Gilead Sciences, Inc.

Kelly A. Kramer, a director of Gilead Sciences, reported the acquisition of stock options and restricted stock units on May 8, 2024.

EVP Deborah H. Telman of Gilead Sciences reports transactions involving common stock and restricted stock units.

Gilead Sciences, a major shareholder in Xilio Therapeutics, has increased its holdings through the purchase of common stock and prefunded warrants.

Gilead Sciences' Chief Medical Officer, Merdad Parsey, sold 2,000 shares of common stock on April 1, 2024, at a price of $72.96 per share, according to a Form 4 filing with the SEC.

Director Kevin E. Lofton reports an acquisition of phantom stock in Gilead Sciences, Inc. through dividend equivalent rights.

EVP Deborah H. Telman reports acquisition and disposal of Gilead Sciences stock and derivative securities.

Sandra Patterson, SVP, Controllership at Gilead Sciences, reports transactions involving common stock and restricted stock units.

Merdad Parsey, Chief Medical Officer of Gilead Sciences, reports transactions involving common stock and restricted stock units, including acquisitions, disposals, and vesting.

Gilead Sciences CEO Daniel O'Day reports acquisition and disposal of common stock and derivative securities, including restricted stock units and stock options, in a recent SEC filing.